Celera Corporation
1401 Harbor Bay Parkway
Alameda
California
94502
United States
Tel: 510-749-4200
Website: http://www.celera.com/
Email: webmaster@celera.com
About Celera Corporation
Celera Corporation, acquired by Quest Diagnostics in May 2011, is a healthcare business that uses knowledge of human variability to provide new tests and services to personalize disease management. Our Products business develops and manufactures molecular diagnostic products that are used by hospitals and other clinical laboratories to detect, characterize, monitor and select treatment for disease. We have a distribution agreement with Abbott, through which we develop and commercialize a wide range of molecular diagnostic products, with Abbott serving as the distribution partner.Our Services business, Berkeley HeartLab, Inc. (BHL), is a high complexity CLIA certified laboratory that offers over 25 clinical diagnostic tests including assays that determine lipoprotein particle size and density based on our proprietary segmented gradient gel electrophoresis technology, along with state-of-the-art genetic testing. These tests identify and characterize risk for cardiovascular disease and help physicians recommend treatment. Our 4myheart centers are staffed with medical professionals who use results from testing at BHL to work with patients, under their physician’s direction, to develop customized regimens for exercise, nutrition, stress management and therapy compliance.
Our internal research and partnering activities fuel the development of new diagnostic tests for personalizing disease management. These new tests are offered as products and/or services.
69 articles about Celera Corporation
-
Quest Diagnostics Inc. Announces Completion of Final Extension of the Subsequent Offering Period and Intent to Exercise Top-Up Option and Complete Merger of Celera Corporation Stocks by Spark Acquisition Corporation
5/11/2011
-
Quest Diagnostics Inc. Extends Tender Offer for all Outstanding Shares of Celera Corporation to May 2, 2011
4/18/2011
-
Quest Diagnostics Inc. Commences Tender Offer for Acquisition of Celera Corporation
3/28/2011
-
Quest Diagnostics India to Buy Celera Corporation for $657 Million
3/22/2011
-
Celera Corporation Delays Filing of 2010 Form 10-K
3/10/2011
-
Celera Corporation to Webcast Presentation at JPMorgan Healthcare Conference
1/6/2011
-
Celera Corporation Files U.S. Regulatory Application for KIF6 Genotyping Assay
1/3/2011
-
Celera Corporation Announces Appointment of Alfred Merriweather as Chief Financial Officer
12/20/2010
-
Celera Corporation Reports Third Quarter 2010 Results
11/4/2010
-
Celera Corporation Posts 21 Percent Q3 Revenue Decline, Will Cut 50 Jobs
11/4/2010
-
Celera Corporation Says Case-Control Publication on KIF6 Does Not Refute Prior Research on KIF6's Association with Coronary Heart Disease and Statin Benefit
10/8/2010
-
Celera Corporation Announces Resignation of Chief Financial Officer
10/5/2010
-
Celera Corporation Announces Issuance of United States Patent Relating to KIF6 Gene Variant as a Predictor of Increased Risk of Myocardial Infarction and Reduction of Such Risk Following Statin Therapy
9/21/2010
-
Celera Corporation Signs Agreement with Abbott Laboratories for Distribution of CE-marked KIF6 Test to Identify Patients at Risk of Coronary Heart Disease
9/20/2010
-
Celera Genomics Group-an Applera Corp. Business Registration Statement Relating to the Separation of Celera Diagnostics from Applera Corporation Declared Effective by the S.E.C.
6/20/2008
-
Celera to Webcast Presentation at Seventh Annual JMP Securities Research Conference
5/15/2008
-
Applera Corporations Board of Directors Formally Approves Proposed Separation of Its Celera Business
5/9/2008
-
Celera Genomics Group-an Applera Corp. Business Reports Third Quarter Fiscal 2008 Results
4/24/2008
-
Celera to Webcast Presentation at Celera Diagnostics Healthcare Conference
4/23/2008
-
Gene Test Can Identify Heart Disease, Spur Cholesterol Drug Use; Celera Diagnostics Publishes Three Papers Demonstrating That Carriers of a Gene Variant are at Elevated Risk of Coronary Heart Disease Which is Virtually Eliminated by Statin Therapy
1/22/2008